We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Zymergen has raised over $400 million in a series C funding round, which it says will help double the capacity of its synthetic biology contract manufacturing platform.....
Roivant, which had one of the biggest initial public offerings in the history of the biotech industry, is a company that focuses on developing and commercializing novel therapies through subsidiary “Vants.”